Adult growth hormone deficiency - benefits, side effects, and risks of growth hormone replacement

Frontiers in Endocrinology

Volumn 4, Issue JUN, 2013, Pages

  Reed, Mary L ^a   Merriam, George R ^b   Kargi, Atil Y ^c  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Adult growth hormone deficiency; Growth hormone; Growth hormone risks; Growth hormone treatment; IGF I; Insulin like growth factor I

Indexed keywords

ARGININE; C REACTIVE PROTEIN; ESTROGEN; FLEXPRO; GLUCOSE; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; HEXARELIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HUMAN GROWTH HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MACIMORELIN; METFORMIN; NORDI FLEX; NUSPIN; PHA 794428; PLACEBO; PRALMORELIN; SEX HORMONE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SUPPRESSOR OF CYTOKINE SIGNALING 2; TESTOSTERONE; UNCLASSIFIED DRUG; VRS 317;

AGING; ARTERIAL WALL THICKNESS; ARTHRALGIA; ATHEROSCLEROSIS; BONE DENSITY; CANCER INCIDENCE; CARDIOVASCULAR DISEASE; CARPAL TUNNEL SYNDROME; CLINICAL FEATURE; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DOSAGE SCHEDULE COMPARISON; DRUG DOSE TITRATION; DRUG MEGADOSE; GROWTH HORMONE DEFICIENCY; GYNECOMASTIA; HODGKIN DISEASE; HORMONE SUBSTITUTION; HUMAN; HYPOGLYCEMIA; HYPOPHYSIS ADENOMA; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; INTRACRANIAL HYPERTENSION; JOINT STIFFNESS; LIPOATROPHY; LOW DRUG DOSE; MORTALITY; MYALGIA; NONHUMAN; PARESTHESIA; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; RECOMMENDED DRUG DOSE; RETINA MACULA EDEMA; REVIEW; SYSTEMATIC REVIEW (TOPIC); TURNER SYNDROME;

EID: 84884190753     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2013.00064     Document Type: Review

References (158)

1. Abs, R., Feldt-Rasmussen, U., Mattsson, A. F., Monson, J. P., Bengtsson, B. A., Gòth, M. I., et al. (2006). Determinants of cardiovascular risk in 2589 hypopituitary GH deficient adults - a KIMS database analysis. Eur. J. Endocrinol. 155, 79-90. doi:10.1530/eje.1.02179
2. Ahmad, A., Hopkins, M. T., Thomas, J., Ibrahim, H., Fraser, W. D., Vora, J. P., et al. (2001). Body composition and quality of life in adults with growth hormone deficiency; effects of low-dose growth hormone replacement. Clin. Endocrinol. 54, 709-717. doi:10.1046/j.1365-2265.2001.01275.x
3. Aimaretti, G., Corneli, G., Razzore, P., Bellone, S., Baffoni, C., Arvat, E., and Etalname, A. (1998). Comparison between insulin induced hypoglycemia and growth hormone (GH) releasing hormone + arginine as provocative tests for the diagnosis of GH deficiency in adults. J. Clin. Endocrinol. Metab. 83, 1615-1618. doi:10.1210/jc.83.5.1615
4. al-Shoumer, K. A., Gray, R., Anyaoku, V., Hughes, C., Beshyah, S., Richmond, W., et al. (1998). Effects of four years' treatment with biosynthetic human growth hormone (GH) on glucose homeostasis, insulin secretion and lipid metabolism in GH-deficient adults. Clin. Endocrinol. (Oxf.) 48, 795-802. doi:10.1046/j.1365- 2265.1998.00460.x
5. Al-Shoumer, K. A., Page, B., Thomas, E., Murphy, M., Beshyah, S. A., and Johnston, D. G. (1996). Effects of four years' treatment with biosynthetic human growth hormone (GH) on body composition in GH-deficient hypopituitary adults. Eur. J. Endocrinol. 135, 559-567. doi:10.1530/eje.0.1350559
6. Amato, G., Carella, C., Fazio, S., La Montagna, G., Cittadini, A., Sabatini, D., et al. (1993). Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses. J. Clin. Endocrinol. Metab. 77, 1671-1676. doi:10.1210/jc.77.6.1671
7. Arnold, J. R., Arnold, D. F., Marland, A., Karavitaki, N., and Wass, J. A. (2009). GH replacement in patients with non-functioning pituitary adenoma (nFa) treated solely by surgery is not associated with increased risk of tumour recurrence. Clin. Endocrinol. (Oxf.) 70, 435-438. doi:10.1111/j.1365-2265.2008.03391.x
8. Bailey, T., Biller, B. M. K., Conway, G. S., Kipnes, M., Popova-Brkic, V., Yuen, K. C. J., et al. (2012). A phase 1 trial of safety, pharmacokinetics (PK) and pharmacodynamics (PD) of a single dose of a new human growth hormone analogue (VRS-317) for monthly subcutaneous administration in adults with growth hormone deficiency. Endocr. Rev. 33, OR29-3 [03_MeetingAbstracts; The Endocrine Society].
9. Baker, L. D., Barsness, S. M., Borson, S., Merriam, G. R., Friedman, S. D., Craft, S., et al. (2012). Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults. Arch. Neurol. 69, 1420-1429.
10. Baroncelli, G. I., Bertelloni, S., Sodini, F., and Saggese, G. (2003). Acquisition of bone mass in normal individuals and in patients with growth hormone deficiency. J. Pediatr. Endocrinol. Metab. 16(Suppl. 2), 327-335.
11. Bates, A. S., Van't Hoff, W., Jones, P. J., and Clayton, R. N. (1996). The effect of hypopituitarism on life expectancy. J. Clin. Endocrinol. Metab. 81, 1169-1172. doi:10.1210/jc.81.3.1169
12. Baum, H. B., Biller, B. M., Finkelstein, J. S., Cannistraro, K. B., Oppenhein, D. S., Schoenfeld, D. A., et al. (1996). Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial. Ann. Intern. Med. 125, 883- 890. doi:10.7326/0003-4819-125-11-199612010-00003
13. Baumann, G. (2012). Growth hormone doping in sports: a critical review of use and detection strategies. Endocr. Rev. 33, 155. doi:10.1210/er.2011-1035
14. Beauregard, C., Utz, A. L., Schaub, A. E., Nachtigall, L., Biller, B. M., Miller, K. K., et al. (2008). Growth hormone decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: a randomized, placebo-controlled study. J. Clin. Endocrinol. Metab. 93, 2063-2071. doi:10.1210/jc.2007-2371
15. Bengtsson, B. A., Sahún, M., Vila, R., Domènech, P., Catalina, P., Soler, J., et al. (2002). The risk of diabetes mellitus in hypopituitary patients on growth hormone substitution. Growth Horm. IGF Res. 12, 302-303.
16. Benvenga, S., Campenní, A., Ruggeri, R. M., and Trimarchi, F. (2000). Hypopituitarism secondary to head trauma. J. Clin. Endocrinol. Metab. 85, 1353-1361. doi:10.1210/jc.85.4.1353
17. Berg, C., Meinel, T., Lahner, H., Yuece, A., Mann, K., and Petersenn, S. (2010). Diagnostic utility of the glucagon stimulation test in comparison to the insulin tolerance test in patients following pituitary surgery. Eur. J. Endocrinol. 162, 477-482. doi:10.1530/EJE-09-0824
18. Beshyah, S., Henderson, A., Niththyanathan, R., Sharp, P., Richmond, W., and Johnston, D. (1994). Metabolic abnormalities in growth hormone deficient adults II: carbohydrate tolerance and lipid metabolism. Endocrinol. Metab. 1, 173-180.
19. Bex, M., Abs, R., Maiter, D., Beckers, A., Lamberigts, G., and Bouillon, R. (2002). The effects of growth hormone replacement therapy on bone metabolism in adultonset growth hormone deficiency: a 2-year open randomized controlled multicenter trial. J. Bone Miner. Res. 17, 1081-1094. doi:10.1359/jbmr.2002.17.6.1081
20. Biller, B., Ji, H. J., and Lee, S. (2010). "Twelve months efficacy and safety novel once-a-week sustained release rhGH (LB03002): a phase III in adults with GH deficiency," in Presented at the 92nd Annual Meeting the Endocrine Society (San Diego, CA). ClinicalTrials.gov identifier: NCT 00596037.
21. Biller, B. M., Samuels, M. H., Zagar, A., Cook, D. M., Arafah, B. M., Bonert, V., et al. (2002). Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency. J. Clin. Endocrinol. Metab. 87, 2067-2079. doi:10.1210/jc.87.5.2067
22. Biller, B. M., Sesmilo, G., Baum, H. B., Hayden, D., Schoenfeld, D., and Klibanski, A. (2000). Withdrawal of long-term physiological growth hormone (GH) administration: differential effects on bone density and body composition in men with adult onset GH deficiency. J. Clin. Endocrinol. Metab. 85, 970-976. doi:10.1210/jc.85.3.970
23. Blackman, M. R., Sorkin, J. D., Münzer, T., Bellantoni, M. F., Busby-Whitehead, J., Stevens, T. E., et al. (2002). Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA 288, 2282-2292. doi:10.1001/jama.288.18.2282
24. Bondanelli, M., De Marinis, L., Ambrosio, M. R., Monesi, M., Valle, D., Zatelli, M. C., et al. (2004). Occurrence of pituitary dysfunction following traumatic brain injury. J. Neurotrauma 21, 685-696. doi:10.1089/0897715041269713
25. Buchfelder, M., Kann, P. H., Wüster, C., Tuschy, U., Saller, B., Brabant, G., et al. (2007). Influence of GH substitution therapy in deficient adults on the recurrence rate of hormonally inactive pituitary adenomas: a case control study. Eur. J. Endocrinol. 157, 149-156. doi:10.1530/EJE-07-0164
26. Carroll, P., Christ, E. R., Bengtsson, B. A., Carlsson, L., Christiansen, J. S., Clemmons, D., et al. (1998). Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee. J. Clin. Endocrinol. Metab. 83, 382-395. doi:10.1210/jc.83.2.382
27. Ceballos, R. (1966). Pituitary changes in head trauma: analysis of 102 consecutive cases of head injury. Ala. J. Med. Sci. 3, 185-198. Chein, E., Daniel, G. V., and Cass, T. (1999). Clinical experiences using a low-dose, high-frequency human growth hormone treatment regimen. J. Adv. Med. 12, 183- 191.
28. Christmas, C., O'Connor, K. G., Harman, S. M., Tobin, J. D., Münzer, T., Bellantoni, M. F., et al. (2002). Growth hormone and sex steroid effects on bone metabolism and bone mineral density in healthy aged women and men. J. Gerontol. A Biol. Sci. Med. Sci. 57, 12-18. doi:10.1093/gerona/57.1.M12
29. Chung, T. T., Drake, W. M., Evanson, J., Walker, D., Plowman, P. N., Chew, S. L., et al. (2005). Tumour surveillance imaging in patients with extrapituitary tumours receiving growth hormone replacement. Clin. Endocrinol. (Oxf.) 63, 274-279. doi:10.1111/j.1365-2265.2005.02338.x
30. Chung, T. T., Evanson, J., Walker, D., Akker, S. A., Besser, G. M., Monson, J. P., et al. (2008). Safety of GH replacement in hypopituitary patients with nonirradiated pituitary and peripituitary tumours. Clin. Endocrinol. (Oxf.) 68, 965-969. doi:10.1111/j.1365-2265.2007.03135.x
31. Cianfarani, S., Clemmons, D. R., and Savage, M. O. (2005). IGF-I and IGF Binding Proteins: Basic Research and Clinical Management. Basel: Karger.
32. Cleland, J. L., Geething, N. C., Moore, J. A., Rogers, B. C., Spink, B. J., Wang, C. W., et al. (2012). A novel long-acting human growth hormone fusion protein (VRS- 317): enhanced in vivo potency and half-life. J. Pharm. Sci. 101, 2744-2754. doi:10.1002/jps.23229
33. Cohen, P., Clemmons, D. R., and Rosenfeld, R. G. (2000). Does the GH-IGF axis play a role in cancer pathogenesis? Growth Horm. IGF Res. 10, 297-305. doi:10.1054/ghir.2000.0171
34. Cohn, L., Feller, A. G., Draper, M. W., Rudman, I. W., and Rudman, D. (1993). Carpal tunnel syndrome and gynaecomastia during growth hormone treatment of elderly men with low circulating IGF-I concentrations. Clin. Endocrinol. (Oxf.) 39, 417-425. doi:10.1111/j.1365-2265.1993.tb02388.x
35. Colao, A., Di Somma, C., Savastano, S., Rota, F., Savanelli, M. C., Aimaretti, G., et al. (2009). A reappraisal of diagnosing GH deficiency in adults: role of gender, age, waist circumference, and body mass index. J. Clin. Endocrinol. Metab. 94, 4414-4422. doi:10.1210/jc.2009-1134
36. Colao, A., Di Somma, C., Spiezia, S., Savastano, S., Rota, F., Savanelli, M. C., et al. (2008). Growth hormone treatment on atherosclerosis: results of a 5-year open, prospective, controlled study in male patients with severe growth hormone deficiency. J. Clin. Endocrinol. Metab. 93, 3416-3424. doi:10.1210/jc.2007-2810
37. Conceição, F. L., da Costa e Silva, A., Leal Costa, A. J., and Vaisman, M. (2003). Glucagon stimulation test for the diagnosis of GH deficiency in adults. J. Endocrinol. Invest. 26, 1065-1070.
38. Cook, D. M., Yuen, K. C., Biller, B. M., Kemp, S. F., and Vance, M. L. American Association of Clinical Endocrinologists. (2009). American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in growth hormone deficient adults and transition patients - 2009 update. Endocr. Pract. 5(Suppl. 2), 1-29. doi:10.4158/EP.15.S2.1
39. Crompton, M. (1971). Hypothalamic lesions following closed head injury. Brain 94, 165-172. doi:10.1093/brain/94.1.165
40. Cuneo, R. C., Salomon, F., McGauley, G. A., and Sönksen, P. H. (1992). The growth hormone deficiency syndrome in adults. Clin. Endocrinol. (Oxf.) 37, 387-397. doi:10.1111/j.1365-2265.1992.tb02347.x
41. Cutfield, W. S., Wilton, P., Bennmarker, H., Albertsson-Wikland, K., Chatelain, P., Ranke, M. B., et al. (2000). Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment. Lancet 355, 610-613. doi:10.1016/S0140-6736(99)04055-6
42. Daniel, P., Prichard, M. M., and Treip, C. S. (1959). Traumatic infarction of the anterior lobe of the pituitary gland. Lancet 2, 927-930. doi:10.1016/S0140-6736(59) 91583-1
43. Deijen, J. B., Arwert, L. I., and Drent, M. L. (2011). The GH/IGF-I axis and cognitive changes across a 4-year period in healthy adults. ISRN Endocrinol. 2011:249421. doi:10.5402/2011/249421
44. Dimopoulou, I., Tsagarakis, S., Theodorakopoulou, M., Douka, E., Zervou, M., Kouyialis, A. T., et al. (2004). Endocrine abnormalities in critical care patients with moderate-to-severe head trauma: incidence, pattern and predisposing factors. Intensive Care Med. 30, 1051-1057. doi:10.1007/s00134-004-2257-x
45. Drake, W. M., Coyte, D., Camacho-Hübner, C., Jivanji, N. M., Kaltsas, G., Wood, D. F., et al. (1998). Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults. J. Clin. Endocrinol. Metab. 83, 3913-3919. doi:10.1210/jc.83.11.3913
46. Drake, W. M., Rodríguez-Arnao, J., Weaver, J. U., James, I. T., Coyte, D., Spector, T. D., et al. (2001). The influence of gender on the short- and long-term effects of growth hormone replacement on bone metabolism and bone mineral density in hypopituitary adults: a 5-year study. Clin. Endocrinol. (Oxf.) 54, 525-532. doi:10.1046/j.1365-2265.2001.01246.x
47. Dupuy, H. J. (1984). "The psychological general well-being (PGWB) index," in Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies, eds N. K. Wenger, M. E. Mattson, C. F. Furberg, and J. Elinson (New York: Le Jacq Publishing), 170-183.
48. Edwards, O. M., and Clark, J. D. A. (1986). Post-traumatic hypopituitarism. Six cases and review of the literature. Medicine (Baltimore) 65, 281-290.
49. EuroQoL Group. (1990). EuroQoL - a new facility for the measurement of health-related quality of life. Health Policy (New York) 16, 199-208. doi:10.1016/0168- 8510(90)90421-9
50. Fisker, S., Jorgensen, J. O., Vahl, N., Orskov, H., and Christiansen, J. S. (1999). Impact of gender and androgen status on IGF-I levels in normal and GH-deficient adults. Eur. J. Endocrinol. 141, 601-608. doi:10.1530/eje.0.1410601
51. Florakis, D., Hung, V., Kaltsas, G., Coyte, D., Jenkins, P. J., Chew, S. L., et al. (2000). Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement: a two year study. Clin. Endocrinol. (Oxf.) 53, 453-459. doi:10.1046/j.1365-2265.2000.01108.x
52. Fradkin, J. E., Mills, J. L., Schonberger, L. B., Wysowski, D. K., Thomson, R., Durako, S. J., et al. (1993). Risk of leukemia after treatment with pituitary growth hormone. JAMA 270, 2829-2832. doi:10.1001/jama.1993.03510230067037
53. Frajese, G., Drake, W. M., Loureiro, R. A., Evanson, J., Coyte, D., Wood, D. F., et al. (2001). Hypothalamopituitary surveillance imaging in hypopituitary patients receiving long-term GH replacement therapy. J. Clin. Endocrinol. Metab. 86, 5172-5175. doi:10.1210/jc.86.11.5172
54. Gaillard, R. C., Mattsson, A. F., Akerblad, A. C., Bengtsson, B. A., Cara, J., Feldt-Rasmussen, U., et al. (2012). Overall and cause-specific mortality in GH-deficient adults on GH replacement. Eur. J. Endocrinol. 166, 1069-1077. doi:10.1530/EJE-11-1028
55. Garcia, J., Swerdloff, R., Wang, C., Kyle, M., Kipnes, M., Biller, B., et al. (2013). Oral macimorelin (AEZS-130) - stimulated growth hormone (GH) test: validation of a novel test for the diagnosis of adult growth hormone deficiency. J. Clin. Endocrinol. Metab. (in press). doi:10.1210/jc.2013-1157
56. Genotropin. (2009). Product Information. New York, NY: Pfizer, Inc
57. Gharib, H., Saenger, P. H., Zimmerman, D., Baskin, H. J., Bengtsson, B.-A., Dickey, R. A., et al. (1998). AACE clinical practice guidelines for growth hormone use in adults and children. Endocr. Pract. 4, 165.
58. Gilchrist, F. J., Murray, R. D., and Shalet, S. M. (2002). The effect of long-term untreated growth hormone deficiency (GHD) and 9 years of GH replacement on the quality of life (QoL) of GH-deficient adults. Clin. Endocrinol. (Oxf.) 57, 363-370. doi:10.1046/j.1365-2265.2002.01608.x
59. Gómez, J. M., Espadero, R. M., Escobar-Jiménez, F., Hawkins, F., Picó, A., Herrera-Pombo, J. L., et al. (2002). Growth hormone release after glucagon as a reliable test of growth hormone assessment in adults. Clin. Endocrinol. 56, 329-334. doi:10.1046/j.1365-2265.2002.01472.x
60. Götherström, G., Elbornsson, M., Stibrant-Sunnerhagen, K., Bengtsson, B. A., Johannsson, G., and Svensson, J. (2009). Ten years of growth hormone (GH) replacement normalizes muscle strength in GH-deficient adults. J. Clin. Endocrinol. Metab. 94, 809-816. doi:10.1210/jc.2008-1538
61. Govardhan, C., Khalaf, N., Jung, C. W., Simeone, B., Higbie, A., Qu, S., et al. (2005). Novel long-acting crystal formulation of human growth hormone. Pharm. Res. 22, 1461-1470. doi:10.1007/s11095-005-6021-x
62. Grimberg, A., and Cohen, P. (1999). Growth hormone and prostate cancer: guilty by association? J. Endocrinol. Invest. 22(5 Suppl.), 64-73.
63. Gunn, I. R., Beastall, G. H., Matthews, D. M., and Bath, J. C. (1991). Post-traumatic hypothalamic-pituitary dysfunction presenting with biochemical features of primary hypothyroidism. Ann. Clin. Biochem. 28, 327-330.
64. Gurlek, A., and Gedik, O. (2001). Endogenous sex steroid, GH and IGF-I levels in normal elderly men: relationships with bone mineral density and markers of bone turnover. J. Endocrinol. Invest. 24, 408-414.
65. Hartman, M. L., Crowe, B. J., Biller, B. M., Ho, K. K., Clemmons, D. R., Chipman, J. J., et al. (2002). Which patients do not require a GH stimulation test for the diagnosis of adult GH deficiency? J. Clin. Endocrinol. Metab. 87, 477-485. doi:10.1210/jc.87.2.477
66. Hatrick, A. G., Boghalo, P., Bingham, J. B., Ayres, A. B., Sonksen, P. H., and Russell-Jones, D. L. (2002). Does GH replacement therapy in adult GH-deficient patients result in recurrence or increase in size of pituitary tumours? Eur. J. Endocrinol. 146, 807-811. doi:10.1530/eje.0.1460807
67. Hazem, A., Elamin, M. B., Bancos, I., Malaga, G., Prutsky, G., Domecq, J. P., et al. (2012). Body composition and quality of life in adults treated with GH therapy: a systematic review and meta-analysis. Eur. J. Endocrinol. 166, 13-20. doi:10.1530/EJE-11-0558
68. Healy, M., and Russell-Jones, D. (1997). Growth hormone and sport: abuse, potential benefits, and difficulties in detection. Br. J. Sports Med. 31, 267-268. doi:10.1136/bjsm.31.4.267
69. Herrmann, B. L., Berg, C., Vogel, E., Nowak, T., Renzing-Koehler, K., Mann, K., et al. (2004). Effects of a combination of recombinant human growth hormone with metformin on glucose metabolism and body composition in patients with metabolic syndrome. Horm. Metab. Res. 36, 54-61. doi:10.1055/s-2004-814199
70. Hilding, A., Hall, K., Wivall-Helleryd, I. L., Sääf, M., Melin, A. L., and Thorén, M. (1999). Serum levels of insulin-like growth factor I in 152 patients with growth hormone deficiency, aged 19-82 years, in relation to those in healthy subjects. J. Clin. Endocrinol. Metab. 84, 2013-2019. doi:10.1210/jc.84.6.2013
71. Ho, K. K., and Participants, G. H. D. C. W. (2007). Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur. J. Endocrinol. 157, 695-700.
72. Hoffman, A., Kuntze, J. E., Baptista, J., Baum, H. B., Baumann, G. P., Biller, B. M., et al. (2004a). Growth hormone replacement therapy in adult-onset GH deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial. J. Clin. Endocrinol. Metab. 89, 2048-2056. doi:10.1210/jc.2003-030346
73. Hoffman, A. R., Strasburger, C. J., Zagar, A., Blum, W. F., Kehely, A., Hartman, M. L., et al. (2004b). T002 Study Group. Efficacy and tolerability of an individualized dosing regimen for adult growth hormone replacement therapy in comparison with fixed body weight-based dosing. J. Clin. Endocrinol. Metab. 89, 3224-3233. doi:10.1210/jc.2003-032082
74. Holloway, L., Kohlmeier, L., Kent, K., and Marcus, R. (1997). Skeletal effects of cyclic recombinant human growth hormone and salmon calcitonin in osteopenic postmenopausal women. J. Clin. Endocrinol. Metab. 82, 1111-1117. doi:10.1210/jc.82.4.1111
75. Holt, R., and Sonksen, P. (2008). Growth hormone, IGF-I and insulin and their abuse in sport. Br. J. Pharmacol. 154, 542-556. doi:10.1038/bjp.2008.99
76. Humatrope. (2009). Product Information. Indianapolis, IN: Eli Lilly and Company
77. Hunt, S. M., and McKenna, S. P. (1992). The QLDS: a scale for the measurement of quality of life in depression. Health Policy (New York) 22, 307-319. doi:10.1016/0168-8510(92)90004-U
78. Hunt, S. M., McKenna, S. P., McEwen, J., Williams, J., and Papp, E. (1981). The Nottingham health profile: subjective health status and medical consultations. Soc. Sci. Med. A 15, 221-229.
79. Johannsson, G., Rosén, T., and Bengtsson, B. A. (1997a). Individualized dose titration of growth hormone (GH) during GH replacement in hypopituitary adults. Clin. Endocrinol. (Oxf.) 47, 571-581. doi:10.1046/j.1365-2265.1997.3271123.x
80. Johannsson, G., Mårin, P., Lönn, L., Ottosson, M., Stenlöf, K., Björntorp, P., et al. (1997b). Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism and reduces diastolic blood pressure. J. Clin. Endocrinol. Metab. 82, 727-734. doi:10.1210/jc.82.3.727
81. Johannsson, G., Rosén, T., Bosaeus, I., Sjöström, L., and Bengtsson, B. A. (1996). Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency. J. Clin. Endocrinol. Metab. 81, 2865-2873. doi:10.1210/jc.81.8.2865
82. Johnson, O. L., Jaworowicz, W., Cleland, J. L., Bailey, L., Charnis, M., Duenas, E., et al. (1997). The stabilization and encapsulation of human growth hormone into biodegradable microspheres. Pharm. Res. 14, 730-735. doi:10.1023/A:1012142204132
83. Jørgensen, J. O., Møller, N., Lauritzen, T., and Christiansen, J. S. (1990). Pulsatile versus continuous intravenous administration of growth hormone (GH) in GHdeficient patients: effects on circulating insulin-like growth factor-I and metabolic indices. J. Clin. Endocrinol. Metab. 70, 1616-1623. doi:10.1210/jcem-70-6-1616
84. Jostel, A., Mukherjee, A., Hulse, P. A., and Shalet, S. M. (2005). Adult growth hormone replacement therapy and neuroimaging surveillance in brain tumour survivors. Clin. Endocrinol. (Oxf.) 62, 698-705. doi:10.1111/j.1365-2265.2005.02282.x
85. Karavitaki, N., Warner, J. T., Marland, A., Shine, B., Ryan, F., Arnold, J., et al. (2006). GH replacement does not increase the risk of recurrence in patients with craniopharyngioma. Clin. Endocrinol. (Oxf.) 64, 556-560. doi:10.1111/j.1365-2265.2006.02508.x
86. Kargi, A., and Merriam, G. (2011). Chapter 2 - age-related changes in the growth hormone axis, and growth hormone therapy in the elderly. Endotext, ed. L. DeGroot. Available at: http://www.endotext.org/aging/aging2/agingframe2.htm/ [accessed February 15, 2013]
87. Kargi, A., and Merriam, G. (2013). Diagnosis and treatment of growth hormone deficiency in adults. Nat. Rev. Endocrinol. 9, 335-345. doi:10.1038/nrendo.2013.77
88. Klasbeek, W., McLaurin, R. L., Harris, B. S. III, and Miller, J. D. (1980). The national head and spinal cord survey findings. J. Neurosurg. 53, 519-531.
89. Koller, E. A., Green, L., Gertner, J. M., Bost, M., and Malozowski, S. N. (1998). Retinal changes mimicking diabetic retinopathy in two nondiabetic, growth hormonetreated patients. J. Clin. Endocrinol. Metab. 83, 2380-2383. doi:10.1210/jc.83.7.2380
90. Koltowska-Häggström, M., Mattsson, A. F., and Shalet, S. M. (2009). Assessment of quality of life in adult patients with GH deficiency: KIMS contribution to clinical practice and pharmacoeconomic evaluations. Eur. J. Endocrinol. 161, S51-S64. doi:10.1530/EJE-09-0266
91. Kornblum, R., and Fisher, R. (1969). Pituitary lesions in craniocerebral injuries. Arch. Pathol. 88, 242-248.
92. Lahm, H., Amstad, P., Wyniger, J., Yilmaz, A., Fischer, J. R., Schreyer, M., et al. (1994). Blockade of the insulin-like growth-factor-I receptor inhibits growth of human colorectal cancer cells: evidence of a functional IGF-II mediated autocrine loop. Int. J. Cancer 58, 452-459. doi:10.1002/ijc.2910580325
93. Laursen, T., Gravholt, C. H., Heickendorff, L., Drustrup, J., Kappelgaard, A. M., Jørgensen, J. O., et al. (2001). Long-term effects of continuous subcutaneous infusion versus daily subcutaneous injections of growth hormone (GH) on the insulin-like growth factor system, insulin sensitivity, body composition, and bone and
94. Laursen, T., Jørgensen, J. O., Jakobsen, G., Hansen, B. L., and Christiansen, J. S. (1995). Continuous infusion versus daily injections of growth hormone (GH) for 4 weeks in GH-deficient patients. J. Clin. Endocrinol. Metab. 80, 2410-2418. doi:10.1210/jc.80.8.2410
95. Laursen, T., Jørgensen, J. O., Susgaard, S., Møller, J., and Christiansen, J. S. (1993). Subcutaneous absorption kinetics of two highly concentrated preparations of recombinant human growth hormone. Ann. Pharmacother. 27, 411-415.
96. Leonsson, M., Hulthe, J., Oscarsson, J., Johannsson, G., Wendelhag, I., Wikstrand, J., et al. (2002). Intima-media thickness in cardiovascularly asymptomatic hypopituitary adults with growth hormone deficiency: relation to body mass index, gender, and other cardiovascular risk factors. Clin. Endocrinol. (Oxf.) 57, 751- 759. doi:10.1046/j.1365-2265.2002.01663.x
97. Lieberman, S. A., Oberoi, A. L., Gilkison, C. R., Masel, B. E., and Urban, R. J. (2008). Prevalence of neuroendocrine dysfunction in patients recovering from traumatic brain injury. J. Clin. Endocrinol. Metab. 86, 2752-2756. doi:10.1210/jc.86.6.2752
98. Liu, H., Bravata, D. M., Olkin, I., Friedlander, A., Liu, V., Roberts, B., et al. (2008). Systematic review: the effects of growth hormone on athletic performance. Ann. Intern. Med. 148, 747-758. doi:10.7326/0003-4819-148-10-200805200-00215
99. Liu, H., Bravata, D. M., Olkin, I., Nayak, S., Roberts, B., Garber, A. M., et al. (2007). Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann. Intern. Med. 146, 104-115. doi:10.7326/0003-4819-146-2-200701160-00005
100. Magnavita, N., Teofili, L., and Leone, G. (1996). Hodgkin's Lymphoma in a cyclist treated with growth hormone. Am. J. Hematol. 52, 65-66. doi:10.1002/(SICI)1096 -8652(199605)52:1<65::AID-AJH16>3.0.CO;2-6
101. Maison, P., and Chanson, P. (2003). Cardiac effects of growth hormone in adults with growth hormone deficiency: a meta-analysis. Circulation 108, 2648-2652. doi:10.1161/01.CIR.0000100720.01867.1D
102. Maison, P., Griffin, S., Nicoue-Beglah, M., Haddad, N., Balkau, B., Chanson, P., et al. (2004). Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a metaanalysis of blinded, randomized, placebo-controlled trials. J. Clin. Endocrinol. Metab. 89, 2192-2199. doi:10.1210/jc.2003- 030840
103. Malozowski, S., and Stadel, B. V. (1995). Benign intracranial hypertension in children with growth hormone deficiency treated with growth hormone. J. Pediatr. 126, 996-999. doi:10.1016/S0022-3476(95)70232-6
104. Malozowski, S., Tanner, L. A., Wysowski, D., and Fleming, G. A. (1993). Growth hormone, insulin-like growth factor I, and benign intracranial hypertension. N. Engl. J. Med. 329, 665-666. doi:10.1056/NEJM199308263290917
105. Masel, B. (2004). Rehabilitation and hypopituitarism after traumatic brain injury. Growth Horm. IGF Res. 14, S108-S113. doi:10.1016/j.ghir.2004.03.024
106. Mauras, N., Pescovitz, O. H., Allada, V., Messig, M., Wajnrajch, M. P., Lippe, B., et al. (2005). Transition Study Group 2005. Limited efficacy of growth hormone (GH) during transition of GH-deficient patients from adolescence to adulthood: a phase III multicenter, double-blind, randomized two-year trial. J. Clin. Endocrinol. Metab. 90, 3946-3955. doi:10.1210/jc.2005-0208
107. McGauley, G. A., Cuneo, R. C., Salomon, F., and Sönksen, P. H. (1990). Psychological well-being before and after growth hormone treatment in adults with growth hormone deficiency. Horm. Res. 33(Suppl. 4), 52-54. doi:10.1159/000181584
108. McGregor, K., and Pentland, B. (1997). Head injury rehabilitation in the U.K.: an economic perspective. Soc. Sci. Med. 45, 295-303. doi:10.1016/S0277-9536(96) 00345-0
109. McKenna, S. P., Doward, L. C., Alonso, J., Kohlmann, T., Niero, M., Prieto, L., et al. (1999). The QoL-AGHDA: an instrument for the assessment of quality of life in adults with growth hormone deficiency. Qual. Life Res. 8, 373-383. doi:10.1023/A:1008884703919
110. Molitch, M. E., Clemmons, D. R., Malozowski, S., Merriam, G. R., and Vance, M. L. Endocrine Society. (2011). Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96, 1587-1609. doi:10.1210/jc.2011-0179
111. Monson, J. P., Jönsson, P., Koltowska-Häggström, M., and Kourides, I. (2007). Growth hormone (GH) replacement decreases serum total and LDL-cholesterol in hypopituitary patients on maintenance HMG CoA reductase inhibitor (statin) therapy. Clin. Endocrinol. (Oxf.) 67, 623-628.
112. Moock, J., Albrecht, C., Friedrich, N., Völzke, H., Nauck, M., Koltowska-Haggström, M., et al. (2009). Health-related quality of life and IGF-1 in GH-deficient adult patients on GH replacement therapy: analysis of the German KIMS data and the Study of Health in Pomerania. Eur. J. Endocrinol. 160, 17-24. doi:10.1530/EJE-08- 0738
113. Murata, M., Kaji, H., Mizuno, I., Sakurai, T., Iida, K., Okimura, Y., et al. (2003). A study of carotid intima-media thickness in GH deficient adults during onset among adults and children. Eur. J. Endocrinol. 148, 333-338. doi:10.1530/eje.0.1480333
114. Murray, R. D., Skillicorn, C. J., Howell, S. J., Lissett, C. A., Rahim, A., Smethurst, L. E., et al. (1999). Influences on quality of life in GH deficient adults and their effect on response to treatment. Clin. Endocrinol. (Oxf.) 51, 565-573. doi:10.1046/j.1365-2265.1999.00838.x
115. National Institutes of Health. (1998). Rehabilitation of persons with traumatic brain injury. NIH Consens. Statement 16, 1-14
116. Norditropin (2010). Product Information. Princeton, NJ: Novo Nordisk Inc
117. Nutropin, A. Q. (2006). Product Information. South San Francisco, CA: Genentech, Inc.
118. Nutropin, A. Q. (2008). Product Information. South San Francisco, CA: Genentech, Inc.
119. O'Halloran, D. J., Tsatsoulis, A., Whitehouse, R. W., Holmes, S. J., Adams, J. E., and Shalet, S. M. (1993). Increased bone density after recombinant human growth hormone (GH) therapy in adults with isolated GH deficiency. J. Clin. Endocrinol. Metab. 76, 1344-1348. doi:10.1210/jc.76.5.1344
120. Olsson, D. S., Buchfelder, M., Schlaffer, S., Bengtsson, B. A., Jakobsson, K. E., Johannsson, G., et al. (2009). Comparing progression of non-functioning pituitary adenomas in hypopituitarism patients with and without long-term GH replacement therapy. Eur. J. Endocrinol. 161, 663-669. doi:10.1530/EJE-09-0572
121. Omnitrope. (2010). Product Information. Princeton, NJ: Sandoz, Inc
122. Park, M. R., Chun, C., Ahn, S. W., Ki, M. H., Cho, C. S., and Song, S. C. (2010). Sustained delivery of human growth hormone using a polyelectrolyte complex loaded thermosensitive polyphosphazene hydrogel. J. Control. Release. 147, 359-367. doi:10.1016/j.jconrel.2010.07.126
123. Péter, F., Bidlingmaier, M., Savoy, C., Ji, H. J., and Saenger, P. H. (2012). Three-year efficacy and safety of LB03002, a once-weekly sustained-release growth hormone (GH) preparation, in prepubertal children with GH deficiency (GHD). J. Clin. Endocrinol. Metab. 97, 400-407. doi:10.1210/jc.2011-2234
124. Pfeifer, M., Verhovec, R., Zizek, B., Prezelj, J., Poredos, P., and Clayton, R. N. (1999). Growth hormone (GH) treatment reverses early atherosclerotic changes in GHdeficient adults. J. Clin. Endocrinol. Metab. 84, 453-457. doi:10.1210/jc.84.2.453
125. Pierucci, G., Gherson, G., and Tavani, M. (1971). Hypophysical alterations in particular necrosis - a sequelae of cranio-encephalic trauma. Pathologica 63, 71-88.
126. Rosén, T., and Bengtsson, B. (1990). Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 336, 285-288. doi:10.1016/0140-6736(90)91812- O
127. Rosilio, M., Blum, W. F., Edwards, D. J., Shavrikova, E. P., Valle, D., Lamberts, S. W., et al. (2004). Long-term improvement of quality of life during growth hormone (GH) replacement therapy in adults with GH deficiency, as measured by questions on life satisfaction-hypopituitarism (QLS-H). J. Clin. Endocrinol. Metab. 89, 1684 -1693. doi:10.1210/jc.2003-030134
128. Rudman, D., Feller, A. G., Nagraj, H. S., Gergans, G. A., Lalitha, P. Y., Goldberg, A. F., et al. (1990). Effects of human growth hormone in men over 60 years old. N. Engl. J. Med. 323, 1-6. doi:10.1056/NEJM199007053230101
129. Saizen. (2007). Product Information. Rockland, MA: EMD Serono, Inc
130. Saller, B., Mattsson, A. F., Kann, P. H., Koppeschaar, H. P., Svensson, J., Pompen, M., et al. (2006). Healthcare utilization, quality of life and patient-reported outcomes during two years of growth hormone (GH) replacement therapy in GH-deficient adults - comparison between Sweden, The Netherlands and Germany. Eur. J. Endocrinol. 15, 843-850. doi:10.1530/eje.1.02149
131. Salomon, F., Cuneo, R. C., Umpleby, A. M., and Sönksen, P. H. (1994). Interactions of body fat and muscle mass with substrate concentrations and fasting insulin levels in adults with growth hormone deficiency. Clin. Sci. 87, 201-206.
132. Schneider, H. J., Kreitschmann-Andermahr, I., Ghigo, E., Stalla, G. K., and Agha, A. (2007). Hypothalamopituitary dysfunction following traumatic brain injury and aneurysmal subarachnoid hemorrhage: a systematic review. JAMA 298, 1429-1438. doi:10.1001/jama.298.12.1429
133. Serostim. (2007). Product Information. Randolph, MA: EMD Serono, Inc
134. Sesmilo, G., Biller, B. M., Llevadot, J., Hayden, D., Hanson, G., Rifai, N., et al. (2000). Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann. Intern. Med. 133, 111-122. doi:10.7326/0003-4819 -133-2-200007180-00010
135. Sesmilo, G., Biller, B. M., Llevadot, J., Hayden, D., Hanson, G., Rifai, N., et al. (2001). Effects of growth hormone (GH) administration on homocysteine levels in men with GH deficiency: a randomized controlled trial. J. Clin. Endocrinol. Metab. 86, 1518-1524. doi:10.1210/jc.86.4.1518
136. Shalet, S. M., Shavrikova, E., Cromer, M., Child, C. J., Keller, E., Zapletalová, J., et al. (2003). Effect of growth hormone (GH) treatment on bone in postpubertal GHdeficient patients: a 2-year randomized, controlled dose-ranging study. J. Clin. Endocrinol. Metab. 88, 4124-4129. doi:10.1210/jc.2003-030126
137. Shim, M., and Cohen, P. (1999). IGFs and human cancer: implications regarding the risk of growth hormone therapy. Horm. Res. 51(Suppl. 3), 42-51. doi:10.1159/000053161
138. Sklar, C. A., Mertens, A. C., Mitby, P., Occhiogrosso, G., Qin, J., Heller, G., et al. (2002). Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. J. Clin. Endocrinol. Metab. 87, 3136-3141. doi:10.1210/jc.87.7.3136
139. Spathis, G. S., Bloom, S. R., Jeffcoate, W. J., Millar, J. G., Kurtz, A., Pyasena, M. R., et al. (1974). Subcutaneous glucagon as a test of the ability of the pituitary to secrete GH and ACTH. Clin. Endocrinol. 3, 175-186. doi:10.1111/j.1365-2265.1974.tb01793.x
140. Stochholm, K., Gravholt, C. H., Laursen, T., Jørgensen, J. O., Laurberg, P., Andersen, M., et al. (2006). Incidence of GH deficiency - a nationwide study. Eur. J. Endocrinol. 155, 61-71. doi:10.1530/eje.1.02191
141. Svensson, J., and Bengtsson, B. (2009). Safety aspects of GH replacement. Eur. J. Endocrinol. 161(Suppl. 1), S65-S74. doi:10.1530/EJE-09-0287
142. Swerdlow, A. J., Higgins, C. D., Adlard, P., and Preece, M. A. (2002). Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study. Lancet 360, 273-277. doi:10.1016/S0140-6736(02)09519-3
143. Takala, J., Ruokonen, E., Webster, N. R., Nielsen, M. S., Zandstra, D. F., Vundelinckx, G., et al. (1999). Increased mortality associated with growth hormone treatment in critically ill adults. N. Engl. J. Med. 341, 785-792. doi:10.1056/NEJM199909093411102
144. Tanriverdi, F., Taheri, S., Ulutabanca, H., Caglayan, A. O., Ozkul, Y., Dundar, M., et al. (2008). Apolipoprotein E3/E3 genotype decreases the risk of pituitary dysfunction after traumatic brain injury due to various causes: preliminary data. J. Neurotrauma 25, 1071-1077. doi:10.1089/neu.2007.0456
145. Tauber, M., De Bouet Du Portal, H., Sallerin-Caute, B., Rochiccioli, P., and Bastide, R. (1993). Differential regulation of serum growth hormone (GH)-binding protein during continuous infusion versus daily injection of recombinant human GH in GH-deficient children. J. Clin. Endocrinol. Metab. 76, 1135-1139. doi:10.1210/jc.76.5.1135
146. Terrio, H., Brenner, L. A., Ivins, B. J., Cho, J. M., Helmick, K., Schwab, K., et al. (2009). Traumatic brain injury screening: preliminary findings in a US Army Brigade Combat Team. J. Head Trauma Rehabil. 24, 14-23. doi:10.1097/HTR.0b013e31819581d8
147. Tev-Tropin. (2007). Product Information. Sellersville, PA: Gate Pharmaceuticals
148. Torrance, G. (1987). Utility approach to measuring health-related quality of life. J. Chronic Dis. 40, 593-600. doi:10.1016/0021-9681(87)90019-1
149. Touraine, P., D'Souza, G. A., Kourides, I., Abs, R., Barclay, P., Xie, R., et al. (2009). GH Lipoatrophy Study Group. Lipoatrophy in GH deficient patients treated with a long-acting pegylated GH. Eur. J. Endocrinol. 161, 533-540. doi:10.1530/EJE-09-0422
150. Underwood, L. E., Attie, K. M., and Baptista, J. Genentech Collaborative Study Group. (2003). Genentech Collaborative Study Group 2003. Growth hormone (GH) dose-response in young adults with childhood-onset GH deficiency: a two-year, multicenter, multiple-dose, placebo-controlled study. J. Clin. Endocrinol. Metab. 88, 5273-5280. doi:10.1210/jc.2003-030204
151. van Baalen, B., Odding, E., Maas, A. I., Ribbers, G. M., Bergen, M. P., and Stam, H. J. (2003). Traumatic brain injury: classification of initial severity and determination of functional outcome. Disabil. Rehabil. 25, 9-18. doi:10.1080/dre.25.1.9.18
152. van Bunderen, C. C., van Nieuwpoort, I. C., Arwert, L. I., Heymans, M. W., Franken, A. A., Koppeschaar, H. P., et al. (2011). Does growth hormone replacement therapy reduce mortality in adults with growth hormone deficiency? Data from the Dutch National Registry of Growth Hormone Treatment in adults. J. Clin. Endocrinol. Metab. 96, 3151-3159. doi:10.1210/jc.2011-1215
153. Varewijck, A. J., Lamberts, S. W., Uitterlinden, P., Hofland, L. J., and Janssen, J. A. (2011). IGF-I bioactivity better reflects growth hormone deficiency than total IGF -I. J. Clin. Endocrinol. Metab. 96, 2248-2254. doi:10.1210/jc.2011-0051
154. Weissberger, A. J., Ho, K. K., and Lazarus, L. (1991). Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. J. Clin. Endocrinol. Metab. 72, 374-381. doi:10.1210/jcem-72-2- 374
155. Widdowson, W., and Gibney, J. (2008). The effect of growth hormone replacement on exercise capacity in patients with GH deficiency: a metaanalysis. J. Clin. Endocrinol. Metab. 93, 4413-4417. doi:10.1210/jc.2008-1239
156. Yuen, K. (2011). Glucagon stimulation testing in assessing for adult growth hormone deficiency: current status and future perspectives. ISRN Endocrinol. 2011:608056. doi:10.5402/2011/608056
157. Yuen, K. C., Biller, B. M., Molitch, M. E., and Cook, D. M. (2009). Clinical review: is lack of recombinant growth hormone (GH)-releasing hormone in the United States a setback or time to consider glucagon testing for adult GH deficiency? J. Clin. Endocrinol. Metab. 94, 2702-2707. doi:10.1210/jc.2009-0299
158. Zorbtive. (2009). Product Information. Rockland, MA: EMD Serono, Inc